No Longer Available EXPANDED_ACCESS NCT00611845

Aprotinin US Special Access Protocol

Aprotinin US Special Access Protocol: An Open Label, Non-Comparative Treatment Protocol for the Use of Aprotinin in Patients Undergoing Coronary Artery Bypass Graft Surgery Requiring Cardiopulmonary Bypass Who Are at Increased Risk of Blood Loss and Transfusion

Sponsor: Bayer

Conditions Postoperative Hemorrhage

Interventions Aprotinin (Trasylol, BAYA0128)

Updated 7 times since 2017 Last updated: Jun 20, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Postoperative Hemorrhage, this trial is ongoing. The trial is conducted by Bayer and has accumulated 7 data snapshots since 2026. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

No Longer Available
Jul 2024 — Sep 2024 [monthly]

No Longer Available
Jan 2021 — Jul 2024 [monthly]

No Longer Available
Jun 2018 — Jan 2021 [monthly]

No Longer Available
Apr 2018 — Jun 2018 [monthly]

No Longer Available

Phase: NA → None

▶ Show 2 earlier versions

Feb 2017 — Apr 2018 [monthly]

No Longer Available NA
Jan 2017 — Feb 2017 [monthly]

No Longer Available NA

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bayer

Data source: Bayer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Asheville, United States , Decatur, United States , Edgewood, United States , Fort Wayne, United States , Glendale, United States , Knoxville, United States , Lynchburg, United States , Medford, United States , Milwaukee, United States , New Brunswick, United States and 6 more locations